Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,621 signal articles · 209 in last 24h · 133,892 total before filter · latest 56m ago
209last 24h
1084last 7d
166● bullish (7d)
127● bearish (7d)
208publishers
AllMacro285Earnings365M&A73Regulatory28Product10Analyst16
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Duolingo shares rise 3.8% after Evercore ISI upgrade
InvestorsHub2d agobullish
Duolingo shares rise 3.8% after Evercore ISI upgrade

Duolingo (NASDAQ:DUOL) shares rose 3. 8% in pre-market trading after Evercore ISI analyst Mark Mahaney upgraded the stock to “Outperform” from “In Line” and raised the firm’s price target to $210.

1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges
StockStory2d agobullish
1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

Strategy Restarts Bitcoin Buying With 4,603 BTC Acquisition
99bitcoins2d agobullish
Strategy Restarts Bitcoin Buying With 4,603 BTC Acquisition

Strategy has made its first bitcoin purchase in two months, acquiring 4,603 BTC for $369.7 million at an average price of $80,318 per coin, according to a Monday morning press release from the company. The purchase lifts Strategy’s total holdings to 845,050 BTC and ends a buying pause. The mechanics ...

Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally
Insider Monkey2d agobullish
Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally

Moderna Inc. (NASDAQ:MRNA) saw its share price soar by 156 percent in August—making it the highest-gaining stock for the month—driven primarily by the strong clinical trial results of its therapy candidate for melanoma, supported by a recent regulatory approval for its updated COVID-19 vaccines. It can be recalled that Moderna and Merck recently partnered for […]